Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma

<i>Background</i>: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options. Recently, we have established a clinically relevant murine HCC model by co-expressing activated forms of v-ak...

Full description

Bibliographic Details
Main Authors: Xianqiong Liu, Junjie Hu, Xinhua Song, Kirsten Utpatel, Yi Zhang, Pan Wang, Xinjun Lu, Jie Zhang, Meng Xu, Tao Su, Li Che, Jingxiao Wang, Matthias Evert, Diego F. Calvisi, Xin Chen
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
hepatocellular carcinoma
MEK inhibitor
pan-mTOR inhibitor
PD901
MLN0128
cell proliferation
apoptosis
Online Access:https://www.mdpi.com/2072-6694/11/7/930

Internet

https://www.mdpi.com/2072-6694/11/7/930

Similar Items